Reuters logo
BRIEF-Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells
May 30, 2017 / 5:11 AM / 4 months ago

BRIEF-Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells

May 30 (Reuters) - CELYAD SA:

* CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below